BR112017008816A2 - álcoois trifluormetílicos como moduladores do roryt - Google Patents

álcoois trifluormetílicos como moduladores do roryt

Info

Publication number
BR112017008816A2
BR112017008816A2 BR112017008816A BR112017008816A BR112017008816A2 BR 112017008816 A2 BR112017008816 A2 BR 112017008816A2 BR 112017008816 A BR112017008816 A BR 112017008816A BR 112017008816 A BR112017008816 A BR 112017008816A BR 112017008816 A2 BR112017008816 A2 BR 112017008816A2
Authority
BR
Brazil
Prior art keywords
syndrome
disorder
disease
roryt modulators
trifluoromethyl alcohols
Prior art date
Application number
BR112017008816A
Other languages
English (en)
Inventor
M Fourie Anne
Gege Christian
Steeneck Christoph
Kleymann Gerald
Venkatesan Hariharan
Kinzel Olaf
Goldberg Steven
Hoffman Thomas
Tanis Virginia
Xue Xiaohua
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54754732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017008816(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority to BR122017023050A priority Critical patent/BR122017023050A2/pt
Publication of BR112017008816A2 publication Critical patent/BR112017008816A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

a presente invenção compreende compostos de fórmula i. fórmula i em que: x, a1, a2, a3, a4, r1, r2 e r3 são definidos no relatório descritivo. a invenção também compreende um método para tratar ou melhorar uma síndrome, distúrbio ou doença, sendo que a dita síndrome, distúrbio ou doença é artrite reumatoide ou psoríase. a invenção também compreende um método de modulação da atividade de ror¿t em um mamífero por meio da administração de uma quantidade terapeuticamente eficaz de pelo menos um composto da reivindicação 1.
BR112017008816A 2014-10-30 2015-10-30 álcoois trifluormetílicos como moduladores do roryt BR112017008816A2 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122017023050A BR122017023050A2 (pt) 2014-10-30 2015-10-30 métodos de preparação de álcoois trifluormetílicos como moduladores do rorgamat

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462072563P 2014-10-30 2014-10-30
PCT/US2015/058193 WO2016069974A1 (en) 2014-10-30 2015-10-30 TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt

Publications (1)

Publication Number Publication Date
BR112017008816A2 true BR112017008816A2 (pt) 2017-12-19

Family

ID=54754732

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112017008816A BR112017008816A2 (pt) 2014-10-30 2015-10-30 álcoois trifluormetílicos como moduladores do roryt
BR122017023050A BR122017023050A2 (pt) 2014-10-30 2015-10-30 métodos de preparação de álcoois trifluormetílicos como moduladores do rorgamat

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122017023050A BR122017023050A2 (pt) 2014-10-30 2015-10-30 métodos de preparação de álcoois trifluormetílicos como moduladores do rorgamat

Country Status (40)

Country Link
US (2) US9850236B2 (pt)
EP (2) EP3212643B1 (pt)
JP (3) JP6998204B2 (pt)
KR (2) KR20170127580A (pt)
CN (3) CN107827841A (pt)
AR (2) AR102480A1 (pt)
AU (2) AU2015339087B2 (pt)
BR (2) BR112017008816A2 (pt)
CA (1) CA2965512C (pt)
CL (3) CL2017001042A1 (pt)
CO (1) CO2017005014A2 (pt)
CR (2) CR20170166A (pt)
CY (1) CY1121716T1 (pt)
DK (1) DK3212643T3 (pt)
EA (2) EA035998B1 (pt)
EC (1) ECSP17033054A (pt)
ES (2) ES2724556T3 (pt)
GT (1) GT201700090A (pt)
HK (1) HK1258212A1 (pt)
HR (1) HRP20190900T1 (pt)
HU (1) HUE043624T2 (pt)
IL (2) IL251865A0 (pt)
JO (2) JOP20200117A1 (pt)
LT (1) LT3212643T (pt)
MA (1) MA40873B1 (pt)
ME (1) ME03426B (pt)
MX (2) MX369567B (pt)
PE (2) PE20180250A1 (pt)
PH (2) PH12017500800A1 (pt)
PL (1) PL3212643T3 (pt)
PT (1) PT3212643T (pt)
RS (1) RS58613B1 (pt)
SG (2) SG11201703323PA (pt)
SI (1) SI3212643T1 (pt)
SV (1) SV2017005429A (pt)
TR (1) TR201907763T4 (pt)
TW (2) TWI667230B (pt)
UY (2) UY36377A (pt)
WO (1) WO2016069974A1 (pt)
ZA (3) ZA201703679B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
BR112020018718A2 (pt) 2018-03-12 2021-03-09 Escalier Biosciences B.V. Moduladores de ror-gama espirocíclicos
EP3765009A4 (en) * 2018-03-12 2021-11-10 Escalier Biosciences, BV BICYCLIC ROR-GAMMA MODULATORS
EP3807261B1 (en) 2018-06-18 2022-07-13 Janssen Pharmaceutica NV Pyridinyl pyrazoles as modulators of roryt
EP3807251B1 (en) * 2018-06-18 2022-09-07 Janssen Pharmaceutica NV Phenyl and pyridinyl substituted imidazoles as modulators of roryt
ES2928246T3 (es) 2018-06-18 2022-11-16 Janssen Pharmaceutica Nv 6-aminopiridin-3-il pirazoles como moduladores de RORyt
CA3103929A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Phenyl substituted pyrazoles as modulators of roryt
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91418A (en) 1988-09-01 1997-11-20 Rhone Poulenc Agrochimie (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them
EP0772606A1 (en) 1994-07-27 1997-05-14 G.D. SEARLE & CO. Substituted thiazoles for the treatment of inflammation
PL367325A1 (en) 2001-04-16 2005-02-21 Tanabe Seiyaku Co, Ltd. Large conductance calcium-activated k channel opener
EP1418911B1 (en) 2001-08-13 2006-05-10 Janssen Pharmaceutica N.V. 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
SA04250288B1 (ar) * 2003-09-19 2008-07-19 سولفاي فارماسوتيكالز بي . في مشتقات ثيازول thiazole كمعدلات لمستقبل المكونات الكيميائية للقنب cannabinoid
US8188128B2 (en) 2005-05-12 2012-05-29 The University Of Medicine And Dentistry Of New Jersey Opioid receptor subtype-selective agents
GB0518237D0 (en) * 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2639910A1 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
WO2008064317A1 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Lipophilic opioid receptor active compounds
WO2008064318A2 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Peripheral opioid receptor active compounds
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
US8809547B2 (en) 2008-07-17 2014-08-19 Bayer Cropscience Ag Heterocyclic compounds as pesticides
EP2417134B1 (en) * 2009-04-08 2017-05-17 Idenix Pharmaceuticals LLC. Macrocyclic serine protease inhibitors
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
EP2368886A1 (en) * 2010-03-01 2011-09-28 Phenex Pharmaceuticals AG Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease
ES2703176T3 (es) 2010-03-11 2019-03-07 Univ New York Compuestos amido como moduladores de RORgammat y usos de los mismos
US9101600B2 (en) 2010-03-11 2015-08-11 New York University Compounds as RORγt modulators and uses thereof
WO2011115892A1 (en) 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
US9505798B2 (en) 2010-11-29 2016-11-29 New York University Steroid compounds as RORyt modulators and uses thereof
KR101958699B1 (ko) 2010-12-28 2019-03-15 라이온 가부시키가이샤 구강 상태의 판정 방법, 그리고 그것을 위해 사용되는 분석 용구, 장치, 및 프로그램
US9012651B2 (en) 2011-03-24 2015-04-21 Abbvie Inc. TRPV3 modulators
US9586928B2 (en) 2011-05-16 2017-03-07 The Scripps Research Institute Modulators of the nuclear hormone receptor ROR
US9156837B2 (en) 2011-07-29 2015-10-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
SG11201400456RA (en) 2011-09-09 2014-04-28 Univ New York Amido compounds as ror?tmodulators and uses thereof
GB201116641D0 (en) * 2011-09-27 2011-11-09 Glaxo Group Ltd Novel compounds
JP5918859B2 (ja) 2011-12-02 2016-05-18 フェネックス ファーマシューティカルス アーゲー オーファン核内受容体ＲＡＲに関連するオーファン受容体−ガンマ（ＲＯＲγ、ＮＲ１Ｆ３）活性の調整剤としての、慢性の炎症性疾患および自己免疫性疾患を治療するためのピロロカルボキサミド
US20130190356A1 (en) 2011-12-22 2013-07-25 Genentech, Inc. Benzyl sulfonamide derivatives as rorc modulators
SG11201407919WA (en) * 2012-05-31 2014-12-30 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
ES2628365T3 (es) * 2012-10-16 2017-08-02 Janssen Pharmaceutica N.V. Moduladores de quinolinilo unidos a fenilo de ROR-GAMA-T
US9624210B2 (en) * 2012-12-12 2017-04-18 Merck Sharp & Dohme Corp. Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors
WO2014195321A1 (en) 2013-06-04 2014-12-11 Acturum Life Science AB Triazole compounds and their use as gamma secretase modulators
CN103333168B (zh) * 2013-07-23 2015-08-05 清华大学 一种酰胺类化合物及其制备方法与应用
WO2015035278A1 (en) 2013-09-09 2015-03-12 Bristol-Myers Squibb Company RORγ MODULATORS
US20150072890A1 (en) 2013-09-11 2015-03-12 20/20 Gene Systems, Inc. Methods and compositions for aiding in the detection of lung cancer
CN105555768B (zh) 2013-09-20 2018-10-16 百时美施贵宝公司 RORγ调节剂
ES2770727T3 (es) * 2013-10-15 2020-07-02 Janssen Pharmaceutica Nv Moduladores de quinilonila enlazados a alquilo de ROR(gamma)t
ES2739621T3 (es) * 2013-10-15 2020-02-03 Janssen Pharmaceutica Nv Moduladores de alcohol secundario de ROR Gamma T de tipo quinolinilo
RS58650B1 (sr) 2013-12-05 2019-05-31 Lead Pharma Holding Bv Ror gama (rory) modulatori
US20160326108A1 (en) 2014-01-06 2016-11-10 Bristol-Myers Squibb Company Pyrrolidinyl sulfone derivatives and their use as ror gamma modulators
US9637455B2 (en) 2014-01-06 2017-05-02 Bristol-Myers Squibb Company Heterocyclic sulfone RORγ modulators
CN106132931B (zh) 2014-01-06 2019-08-02 百时美施贵宝公司 碳环砜RORγ调节剂
ES2704460T3 (es) 2014-01-06 2019-03-18 Bristol Myers Squibb Co Moduladores de ROR gamma de ciclohexilsulfona
EP3122721A4 (en) 2014-03-27 2018-01-10 Piramal Enterprises Limited Ror-gamma modulators and uses thereof
KR20170075787A (ko) 2014-10-30 2017-07-03 얀센 파마슈티카 엔.브이. RORγt의 조절제로서의 아미드 치환된 티아졸
PL3212641T3 (pl) 2014-10-30 2019-05-31 Janssen Pharmaceutica Nv Tiazole jako modulatory RORYT

Also Published As

Publication number Publication date
ECSP17033054A (es) 2018-01-31
US10150762B2 (en) 2018-12-11
US9850236B2 (en) 2017-12-26
HUE043624T2 (hu) 2019-08-28
SG10201805355YA (en) 2018-07-30
CL2018000436A1 (es) 2018-07-06
AU2015339087A1 (en) 2017-05-11
AR110155A2 (es) 2019-02-27
SG11201703323PA (en) 2017-05-30
LT3212643T (lt) 2019-06-10
HRP20190900T1 (hr) 2019-07-12
IL251865A0 (en) 2017-06-29
IL255648B (en) 2020-06-30
EA033699B1 (ru) 2019-11-18
UY36377A (es) 2016-04-29
PH12017502105A1 (en) 2019-11-25
ME03426B (me) 2020-01-20
MX2017005689A (es) 2018-02-19
RS58613B1 (sr) 2019-05-31
CY1121716T1 (el) 2020-07-31
TWI705057B (zh) 2020-09-21
JP6998204B2 (ja) 2022-02-04
PE20180250A1 (es) 2018-02-02
CR20170166A (es) 2017-08-22
SI3212643T1 (sl) 2019-04-30
HK1258212A1 (zh) 2019-11-08
EP3354651B1 (en) 2021-01-06
EA035998B1 (ru) 2020-09-10
MX369567B (es) 2019-11-12
AR102480A1 (es) 2017-03-01
ZA201805860B (en) 2019-11-27
TW201629027A (zh) 2016-08-16
JP2020180129A (ja) 2020-11-05
CN112979630A (zh) 2021-06-18
EP3354651A1 (en) 2018-08-01
KR20170078750A (ko) 2017-07-07
ZA201703679B (en) 2019-06-26
ES2858503T3 (es) 2021-09-30
JP2018500287A (ja) 2018-01-11
BR122017023050A2 (pt) 2019-09-10
UY37517A (es) 2018-01-31
PE20171649A1 (es) 2017-11-13
ZA201805861B (en) 2019-11-27
EA201891562A2 (ru) 2018-12-28
GT201700090A (es) 2019-08-08
PT3212643T (pt) 2019-06-17
EA201891562A3 (ru) 2019-04-30
IL255648A (en) 2018-01-31
EP3212643B1 (en) 2019-03-20
PH12017500800B1 (en) 2017-10-02
DK3212643T3 (da) 2019-05-13
EA201790942A1 (ru) 2017-09-29
CA2965512A1 (en) 2016-05-06
JP2019059728A (ja) 2019-04-18
CR20170542A (es) 2018-02-20
AU2015339087B2 (en) 2020-01-23
KR20170127580A (ko) 2017-11-21
CO2017005014A2 (es) 2017-08-31
PH12017500800A1 (en) 2017-10-02
JO3571B1 (ar) 2020-07-05
TR201907763T4 (tr) 2019-06-21
MX367912B (es) 2019-09-11
PL3212643T3 (pl) 2019-08-30
AU2019200228A1 (en) 2019-01-31
EP3212643A1 (en) 2017-09-06
CL2017001042A1 (es) 2017-12-01
CA2965512C (en) 2020-03-10
JOP20200117A1 (ar) 2017-06-16
AU2019200228B2 (en) 2020-04-16
WO2016069974A1 (en) 2016-05-06
CN107108599A (zh) 2017-08-29
TWI667230B (zh) 2019-08-01
CN107827841A (zh) 2018-03-23
ES2724556T3 (es) 2019-09-12
US20160122336A1 (en) 2016-05-05
MA40873A (fr) 2017-09-05
SV2017005429A (es) 2017-10-17
CL2019001514A1 (es) 2019-10-04
TW201927759A (zh) 2019-07-16
MA40873B1 (fr) 2019-07-31
JP6623270B2 (ja) 2019-12-18
US20170327492A1 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
BR112017008816A2 (pt) álcoois trifluormetílicos como moduladores do roryt
BR112017008852A2 (pt) tiazóis substituídos com amida como moduladores do roryt
BR112017008842A2 (pt) tiazóis como moduladores de ror?t
BR112016008258A2 (pt) moduladores de ror?t de quinolinila
PH12018502209A1 (en) 6-aminopyridin - 3 - yl thiazoles as modulators of ror gamma t
BR112018004620A2 (pt) moduladores da expressão de kras
DOP2016000286A (es) Compuesto heterocíclico que contiene nitrógeno
MY189505A (en) Methylene linked quinolinyl modulators of roryt
BR112017028194A2 (pt) moduladores de diaciglicerol aciltransferase 2 (dgat2)
PH12015500776A1 (en) Phenyl linked quinolinyl modulators of ror-gamma-t
PH12016502062A1 (en) Compositions and methods for modulating completent factor b expression
BR112016008215A2 (pt) moduladores de quinolinila ligados por alquila de roryt
BR112017015912A2 (pt) reator de leito inclinado que permite utilizar uma pequena quantidade de catalisador
BR112016008201A2 (pt) Moduladores de quinolinila ligados à heteroarila de roryt
BR112016008257A2 (pt) moduladores de roryt de álcool quinolínico secundário
MX2020007369A (es) Moduladores de la expresion de dnm2.
BR112016008183A2 (pt) Moduladores de ror-gama-t de quinolinila ligados à fenila

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements